 |
|
|
|
 |
|
|
| Article 1 to 10 out of 23 concerning Pfizer Inc.
|
-
EU funded systems biology consortium for adipositas induced type-2 diabetes reports first results
(07/04/2008)
SysProt reports identification of a novel regulatory protein that appears to be involved in the development of obesity-induced type-2 diabetes in a mouse model for the human metabolic syndrome. The systems biology project SysProt (System-wide ...
-
NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program
(05/07/2008)
NicOx S.A. announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan® (latanoprost) 0.005% in patients with primary open-angle glaucoma and ...
-
NicOx signs extension of ophthalmology agreement with Pfizer
(01/09/2008)
NicOx S.A. announced it has signed an extension of its March 2006 collaboration agreement, which grants Pfizer Inc the exclusive right to apply its proprietary nitric oxide-donating technology to drug discovery research in the field of ...
-
Graffinity Announces Multitarget Drug Discovery Research Collaboration With Pfizer
(11/30/2007)
Graffinity Pharmaceuticals GmbH announced that it has entered into its second drug discovery collaboration with Pfizer, Inc. Through the collaboration, Graffinity will provide Pfizer with access to its proprietary, fragment-based screening ...
-
Pfizer to Acquire Coley Pharmaceutical Group
(11/22/2007)
Acquisition Will Expand Pfizer's Investment in Vaccines
Pfizer Inc announced it has entered into an agreement to acquire Coley Pharmaceutical Group, Inc., a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to ...
-
DIREVO and Pfizer collaborate on therapeutic proteases
(11/13/2007)
DIREVO Biotech AG announced the signing of a collaboration agreement with Pfizer, Inc., New York, to develop therapeutic proteases for different targets as potential treatments for various diseases. Direvo will apply its protein-engineering ...
-
Crucell Announces PER.C6® Licensing Agreement with Pfizer Animal Health
(03/19/2007)
Crucell N.V. and Pfizer Animal Health announced the signing of a research license agreement for PER.C6®. The license agreement allows Pfizer Animal Health to use Crucell's PER.C6® cell technology in the production of a non-disclosed veterinary ...
-
SR Pharma plc Announces Start of Phase I trial with Novel RNAi Therapeutic RTP-801i in Age- related Macular Degeneration (AMD)
(02/07/2007)
SR Pharma plc announced that Quark Biotech Inc. has started a Phase I clinical trial with RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma plc. RTP-801i is based on Atugen's proprietary ...
-
Genizon Biosciences Announces a License and Collaboration Agreement with Pfizer in Three Major Diseases
(01/18/2007)
Collaboration using "Quebec Founder Population" in genome-wide association studies to be used to develop diagnostics
Genizon BioSciences announced a license and collaboration agreement with Pfizer Inc. for diagnostic rights to Genizon's discovery programs in Alzheimer's disease, attention deficit hyperactivity disorder and endometriosis. Genizon retains ...
-
Archemix Announces Collaboration with Pfizer to Discover Aptamer Therapeutics
(01/11/2007)
Archemix Corp. announced that it has signed an agreement with Pfizer focused on the discovery of first-in-class aptamers for the development and commercialization as therapeutics. As part of the collaboration, Archemix will use its proprietary SELEX ...
|
|
|
|
|
Top